LISA LAYMAN

HOOPER, LUNDY & BOOKMAN, P.C. · Washington, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

last 3 years

Filings

2 agencies contacted

Activity

filings by quarter

Works on

Health Issues 14 Medicare/Medicaid 11 Insurance 3 Medical/Disease Research/Clinical Labs 2 Budget/Appropriations 1

Background

Government experience

SPA

Sen Stabenow

2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996

Disclosed on LD-2 filings

SPA

Sen Stabenow

2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996

Disclosed on LD-2 filings

SPA

Sen. Stabenow

2005-2007); SPA Sen. Graham (2001-2004); LA, Sen. Bryan (2000); LA, Sen. Chafee (1997-1999); CBO, PA (1992-1996

Disclosed on LD-2 filings

SPA

Sen. Stabenow

2005-2007); SPA, Sen. Graham (2001-2004); LA, Sen. Bryan (2000); LA, Sen. Chafee (1997-199); CBO, PA (1992-1996

Disclosed on LD-2 filings

SPA

Sen. Stabenow

2005-2007); SPA, Sen. Graham (2001-2004); LA, Sen. Bryan (2000); LA, Sen. Chafee (1997-1999); CBO, PA (1992-1996

Disclosed on LD-2 filings

SPA

Sen Stabenow

2005-2007); SPA, Sen Graham (2001 -2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996

Disclosed on LD-2 filings

Career

HOOPER, LUNDY & BOOKMAN, P.C.

Washington, DC

2024 - present

Specific issues

Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.

Health Issues · 2024 Q3

S. 1339 - Pharmacy Benefit Manager Reform Act; H.R. 5378 -Lower Costs, More Transparency Act; S. 1542/H.R. 6283 -The Delinking Revenue from Unfair Gouging (DRUG) Act; S. 127 - Pharmacy Benefit Manager Transparency Act of 2023.

Health Issues · 2024 Q3

S. 2973-Modernizing and Ensuring PBM Accountability Act; S. 3430 - Better Mental Healthcare, Lower Cost Drugs & Extenders Act (provisions related to PBMs and pharmacy contracting); H.R. 5526 - Seniors Access to Critical Medications Act of 2023; H.R. 7623 - Telehealth Modernization Act of 2024

Medicare/Medicaid · 2024 Q3

H.R. 1342/S. 570 Medicaid Dental Benefit Act of 2023.

Medicare/Medicaid · 2024 Q3

H.R. 1385/S. 1424 DOC Access Act of 2023.

Insurance · 2024 Q3

H.R. 1671/S. 2771 Increasing Access to Dental Insurance Act; Issues related to operation of the Affordable Care Act exchanges, Issues related to expanding access to dental benefits.

Health Issues · 2024 Q3